<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309111</url>
  </required_header>
  <id_info>
    <org_study_id>ISB 1342-101</org_study_id>
    <secondary_id>2016-005253-20</secondary_id>
    <nct_id>NCT03309111</nct_id>
  </id_info>
  <brief_title>Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma</brief_title>
  <official_title>A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects With Previously Treated Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ichnos Sciences SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glenmark Pharmaceuticals S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ichnos Sciences SA</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic&#xD;
      (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, multi-center, Phase 1 study of ISB 1342 in subjects with&#xD;
      relapsed/refractory multiple myeloma refractory to proteasome inhibitors (PIs),&#xD;
      immunomodulators (IMiDs), and daratumumab. There will be a dose escalation phase (Part 1) and&#xD;
      dose expansion phase (Part 2). In Part 1 of the study, subjects will be treated at escalating&#xD;
      dose levels. Once the recommended part 2 dose (RP2D) of ISB 1342 is declared in Part 1, the&#xD;
      expansion phase (Part 2) will be initiated at the RP2D.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2017</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal tolerated dose (MTD) and/or recommended part 2 dose (RP2D) of ISB 1342 (Part 1)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator-assessed objective response (complete response [CR], stringent CR [sCR], partial response [PR], very good PR [VGPR], minimal response [MR]) to ISB 1342, according to international myeloma working group (IMWG) criteria (Part 2)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events based on relatedness and severity as assessed by common terminology criteria for adverse events (CTCAE) v5.0</measure>
    <time_frame>up to 30 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of ISB 1342</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum observed plasma concentration (Tmax) of ISB 1342</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration time curve from zero to time t (AUC0-t) of ISB 1342</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time zero to end of dosing interval (AUC0-tau) of ISB 1342</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of ISB 1342 by anti-drug antibody (ADA) formation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ISB 1342 (duration of response [DOR]) (Part 2)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ISB 1342 (disease control rate [DCR]) (Part 2)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">197</enrollment>
  <condition>Relapsed/Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ISB 1342</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Cohorts of multiple ISB 1342 dose levels; Part 2: One dose regimen until disease progression or other discontinuation criterion is met</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ISB 1342</intervention_name>
    <description>ISB-1342 is CD38 x CD3 BEATÂ® 1.0 bispecific antibody. ISB 1342 is administered by intravenous (IV) infusion</description>
    <arm_group_label>ISB 1342</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of relapsed/refractory multiple myeloma with measurable disease&#xD;
             (serum, urine, or free light chain) per International Myeloma Working Group (IMWG)&#xD;
             criteria&#xD;
&#xD;
          -  Patients have received proteasome inhibitor, immunomodulator, and daratumumab&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance-status score of 2 or less&#xD;
&#xD;
          -  Adequate hematologic, renal, and hepatic functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active central nervous system involvement&#xD;
&#xD;
          -  Exposure to daratumumab within 6 months prior to the start of study treatment&#xD;
&#xD;
          -  Active plasma cell leukemia&#xD;
&#xD;
          -  Blood transfusion and/or granulocyte-(macrophage) colony-stimulating factor&#xD;
&#xD;
          -  Active infectious disease&#xD;
&#xD;
          -  Clinically significant cardiovascular and respiratory conditions&#xD;
&#xD;
          -  History of HIV infection or acute or chronic active hepatitis B or C infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ichnos Sciences Clinical Trials Administrator</last_name>
    <phone>(315) 583-1249</phone>
    <email>clinicaltrials@ichnossciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ichnos Investigational Site 2</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ichnos Investigational Site 11</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ichnos Investigational Site 3</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Ann Huff, MD</last_name>
      <email>huffca@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ichnos Investigational Site 10</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prashant Kapoor, MD</last_name>
      <email>Kapoor.Prashant@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ichnos Investigational Site 1</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ichnos Investigational Site 5</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Richter, MD</last_name>
      <email>joshua.richter@mountsinai.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ichnos Investigational Site 7</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Lesokhin, MD</last_name>
      <email>lesokhia@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ichnos Investigational Site 9</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristiana Costa Chase, MD</last_name>
      <email>cristiana.costa@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ichnos Investigational Site 6</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Berdeja, MD</last_name>
      <email>jberdeja@tnonc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ichnos Investigational Site 8</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Mohan, MD</last_name>
      <email>sanjay.mohan@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ichnos Investigational Site 4</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

